Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
We report a favorable response rate when combining a selective PI3K pathway inhibitor and taxane in patients with anti-PD-1 refractory HNSCC.
Authors
- R. Shi (ORCID: https://orcid.org/0000-0002-3779-2692)
- N. Quinn (ORCID: https://orcid.org/0000-0002-9654-3944)
- Michael J. Dennis (ORCID: https://orcid.org/0000-0002-8175-5311)
- Kee‐Young Shin (ORCID: https://orcid.org/0000-0002-3451-8516)
- Vickie Y. Jo (ORCID: https://orcid.org/0000-0003-4808-2714)
- Glenn J. Hanna (ORCID: https://orcid.org/0000-0002-9969-2523)
- A. Tkachuk
- Kristine Wong (ORCID: https://orcid.org/0000-0003-4139-1581)
- Kartik Sehgal (ORCID: https://orcid.org/0000-0003-4391-6943)
- K. Kryukov
- Sheila Waters (ORCID: https://orcid.org/0009-0002-3728-1486)
- A. O’Neill (ORCID: https://orcid.org/0009-0002-7334-4560)
- Владимир Кушнарев (ORCID: https://orcid.org/0000-0003-4608-9349)
- Jochen K. Lennerz (ORCID: https://orcid.org/0000-0003-2434-4978)
- Robert I. Haddad (ORCID: https://orcid.org/0000-0003-1413-0079)
- B. U. Shanthappa
- Viktor Svekolkin (ORCID: https://orcid.org/0000-0001-5763-7246)
- A. Sarachakov
- Nicole Scarfo (ORCID: https://orcid.org/0009-0003-9512-1015)
- L. B. Oakley
- A. Shvyrkova (ORCID: https://orcid.org/0000-0002-8742-6295)
Institutions
- Brigham and Women's Hospital (US)
- Addgene (US)
- Dana-Farber Cancer Institute (US)
- AMPAC Fine Chemicals (United States) (US)
- Cabot (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2262
- Citations
- 6
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.51
Funders
- Gateway for Cancer Research
- Genentech